Clinical trials: in Laos
Strongyloides Stercoralis Infection
Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis
This study is a phase 2, blinded and randomized clinical trial. The phase 2a trial is single blinded and conducted in Lao, while the phase 2b trial is double-blinded and conducted in Lao and Cambodia.
- Trial name
- StrongMoxi (NCT04056325)
- Testing
- Moxidectin, Ivermectin
- Where
- Laos
- Volunteers
- 617 people
- Sponsor
- Jennifer Keiser
Cigarette Smoking
Mobile Health Technology for Personalized Tobacco Cessation Support Among Cancer Survivors in Laos
The parent project (1R21CA253600-01, R21 phase: 9/1/2020-8/31/2022, R33 phase: 9/1/2022-8/31/2025) aims to adapt and evaluate the efficacy of our theoretically and empirically based mobile health (mHealth) technology to help…
- Trial name
- SurvLaos (NCT05253573)
- Testing
- Nicotine patch, Self-help materials (to support smoking cessation), Smartphone-based automated treatment for smoking cessation
- Where
- 2 sites in Laos
- Volunteers
- 80 people
- Sponsor
- University of Oklahoma
Trichuriasis
Efficacy and Safety of IVM/ALB Co-administration
This study is a double-blind randomized clinical trial conducted with two settings in Africa and one in Asia, namely Côte d'Ivoire, Pemba (Zanzibar, Tanzania) and Lao PDR.
- Trial name
- NCT03527732
- Testing
- Albendazole, Albendazole and Ivermectin
- Where
- 3 sites in Côte d’Ivoire, Laos and 1 more
- Volunteers
- 1,673 people
- Sponsor
- Jennifer Keiser